Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss.

This study involves (3) in-person study visits. At each visit, participants will be asked to:

* Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs. * Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength. * Complete questionnaires related to demographics, health information, physical activity, and nutrition. * Have a blood sample collected from a vein in your arm. * Have your blood levels assessed through three finger pricks. * Complete three days of food records.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Type 2 Diabetes Body Weight Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases GLP-1 Glucose Metabolism Disorders Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Semaglutide Signs and Symptoms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Mazankowski Alberta Heart Institute

Edmonton, Alberta, T6G 0M9, Canada

Location status: Recruiting

Location contact

Krista Jong

CONTACT

[email protected]

780-492-9010

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults 18-80 years of age
Starting semaglutide for type 2 diabetes or weight loss
Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)

Exclusion criteria

Current use of semaglutide for more than 2 weeks
Major recent heart issues or other severe health conditions
Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia)
Dependence on a mobility aid (unable to participate in exercise MRI)

Treatment and study plan

Primary outcomes

Changes in skeletal and cardiac muscle mass

Time frame: 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Krista Jong, RD, BSc

CONTACT

[email protected]

780-492-9010

Sponsors and collaborators

Lead sponsor

University of Alberta

Other

Registry information

Official study title

GLP-1 Receptor Agonist-Induced Muscle Mass Evaluation and Retention

Acronym: GLIMMER

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2028
First posted: Dec 9, 2025
Registry last updated: Jul 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting